PEP-Therapy is a clinical-stage biotechnology company developing first-in-class peptides as targeted therapies in oncology based on the Company’s innovative Cell Penetrating and Interfering Peptides (CP&IP) technology. These innovative molecules penetrate cells and specifically block relevant intracellular protein-protein interactions, leading to the inhibition of key pathological mechanisms without altering physiological mechanisms.
PEP-010, first CP&IP-based drug candidate, is a pro-apoptotic agent which has demonstrated anti-tumor efficacy in a number of pre-clinical models and a good safety profile. PEP-010 is currently evaluated in a Phase Ia/b clinical trial in patients with recurrent and/or metastatic solid tumors. PEP-Therapy was founded in 2014 and builds on research results from Institut Curie and Sorbonne University. The company is backed by international investors.
Total Funding: €7.9 M
Funding Stage: Series A
Business Stage: N/A
Market: B2B
Company Size: 1 to 25
Founded: 2014
Oct 2021
- PEP-Therapy and Institut Curie Announced First Patients Dosed in Phase I Clinical Trial
Mar 2021
- PEP-Therapy and Institut Curie Granted Approval
Oct 2019
- PEP-Therapy Part of the Laureates of ReAliZe
